Pfizer (PFE) Trades Higher After Better-Than-Expected Third Quarter Results
Tweet
Share
E-mail
Get Alerts PFE Hot Sheet
Price: $27.89 +0.54%
EPS Growth %: -12.6%
Financial Fact:
Cash dividends paid per common share (in dollars per share): 0.3
Today's EPS Names:
OCCI, ALZN, ASPU, More
EPS Growth %: -12.6%
Financial Fact:
Cash dividends paid per common share (in dollars per share): 0.3
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
This morning, pharmaceutical giant Pfizer Inc. (NYSE: PFE) topped third quarter EPS and revenue views. The company reported adjusted EPS of $0.51, versus the consensus of $0.48. While Pfizer reported a 3% drop in revenue to $11.6 billion, the results topped Wall Street views of $11.42 billion. The company attributed the drop in revenue in large part to the unfavorable foreign exchange rates which caused a 4% decline in international revenue from the year-ago quarter.
The 2009 revenues for Pfizer is projected at $49-$50 billion, against the previous guidance of $45-$46 billion and the consensus of $45.3 Billion. Pfizer sees FY EPS of $2.00-$2.05, versus prior guidance of $$1.90-$2.00 and the consensus of $1.98.
"We are pleased with our results this quarter and in our ability to once again deliver solid operational performance in an environment that continues to be challenging," stated Jeff Kindler, Chairman and Chief Executive Officer.
The company is optimistic that despite the poor foreign exchange, that it will be able to continue to meet its commitments with the strong performance of its five Pharmaceutical units and Animal Health business which reflect Pfizer’s 5% operational growth in the last quarter.
"We are beginning to implement our integration plan in order to quickly maximize the value of our expanded and more diversified global product portfolio in key high-growth areas," Kindler added.
Current market movement for Pfizer (NYSE: PFE) is +2.61% before the market opens.
The 2009 revenues for Pfizer is projected at $49-$50 billion, against the previous guidance of $45-$46 billion and the consensus of $45.3 Billion. Pfizer sees FY EPS of $2.00-$2.05, versus prior guidance of $$1.90-$2.00 and the consensus of $1.98.
"We are pleased with our results this quarter and in our ability to once again deliver solid operational performance in an environment that continues to be challenging," stated Jeff Kindler, Chairman and Chief Executive Officer.
The company is optimistic that despite the poor foreign exchange, that it will be able to continue to meet its commitments with the strong performance of its five Pharmaceutical units and Animal Health business which reflect Pfizer’s 5% operational growth in the last quarter.
"We are beginning to implement our integration plan in order to quickly maximize the value of our expanded and more diversified global product portfolio in key high-growth areas," Kindler added.
Current market movement for Pfizer (NYSE: PFE) is +2.61% before the market opens.
You May Also Be Interested In
- Pfizer Invites Public to View and Listen to Webcast of November 3 Conference Call with Analysts
- Ennis (EBF) Misses Q2 EPS by 2c
- Thor Industries (THO) Misses Q4 EPS by 13c
Create E-mail Alert Related Categories
Earnings, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
